233 related articles for article (PubMed ID: 26810416)
1. Balancing cardiovascular and gastrointestinal risks in patients with osteoarthritis receiving nonsteroidal anti‑inflammatory drugs. A summary of guidelines from an international expert group.
Mosleh W; Farkouh ME
Pol Arch Med Wewn; 2016; 126(1-2):68-75. PubMed ID: 26810416
[TBL] [Abstract][Full Text] [Related]
2. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
3. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
4. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks.
Scarpignato C; Lanas A; Blandizzi C; Lems WF; Hermann M; Hunt RH;
BMC Med; 2015 Mar; 13():55. PubMed ID: 25857826
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
6. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
Chan FK; Abraham NS; Scheiman JM; Laine L;
Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
[TBL] [Abstract][Full Text] [Related]
7. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
Davies NM; Reynolds JK; Undeberg MR; Gates BJ; Ohgami Y; Vega-Villa KR
Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779
[TBL] [Abstract][Full Text] [Related]
8. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
Chaiamnuay S; Allison JJ; Curtis JR
Am J Health Syst Pharm; 2006 Oct; 63(19):1837-51. PubMed ID: 16990630
[TBL] [Abstract][Full Text] [Related]
9. NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians.
Scheiman JM
J Clin Gastroenterol; 2016 Jan; 50(1):5-10. PubMed ID: 26524151
[TBL] [Abstract][Full Text] [Related]
10. The NSAID dilemma: managing osteoarthritis in high-risk patients.
Roth SH; Anderson S
Phys Sportsmed; 2011 Sep; 39(3):62-74. PubMed ID: 22030942
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention.
Scarpignato C; Hunt RH
Gastroenterol Clin North Am; 2010 Sep; 39(3):433-64. PubMed ID: 20951911
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of NSAIDs prescribing in Saudi Arabia: Cardiovascular and gastrointestinal risk in patients with diabetes mellitus
.
Mazhar F; Haider N; Sultana J; Akram S; Ahmed Y
Int J Clin Pharmacol Ther; 2018 Feb; 56(2):64-71. PubMed ID: 29208206
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
Borer JS; Simon LS
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular and gastrointestinal safety of NSAIDs].
van den Bemt P; Tjwa ET; van Oijen MG
Ned Tijdschr Geneeskd; 2014; 158():A7311. PubMed ID: 24713339
[TBL] [Abstract][Full Text] [Related]
15. The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment.
Chan FK
Am J Gastroenterol; 2008 Jan; 103(1):221-7. PubMed ID: 17900323
[TBL] [Abstract][Full Text] [Related]
16. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs.
García-Rayado G; Navarro M; Lanas A
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1031-1043. PubMed ID: 30139288
[TBL] [Abstract][Full Text] [Related]
17. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study.
Lanas A; Tornero J; Zamorano JL
Ann Rheum Dis; 2010 Aug; 69(8):1453-8. PubMed ID: 20498210
[TBL] [Abstract][Full Text] [Related]
18. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs.
Peura DA; Goldkind L
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S7-13. PubMed ID: 16168079
[TBL] [Abstract][Full Text] [Related]
19. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.
Lanas A; Garcia-Tell G; Armada B; Oteo-Alvaro A
BMC Med; 2011 Apr; 9():38. PubMed ID: 21489310
[TBL] [Abstract][Full Text] [Related]
20. [A choice of a nonsteroidal anti-inflammatory drug with regard to gastrointestinal and cardiovascular' risks].
Pakhomova IG
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(4):85-89. PubMed ID: 27386591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
